Alejandro Alagón Cano
Alejandro Alagón Cano is a Mexican doctor, researcher, professor and academic. He was an active researcher during the development process of the scorpion antivenom Alacramyn and the pit viper antivenom Antivipmyn, both manufactured by Instituto Bioclon in Mexico. These products were later approved for commercial distribution by the United States Food and Drug Administration (FDA) in 2011 and 2015 and are marketed under the names Anascorp and Anavip, respectively. Education
Alagón completed his undergraduate degree at the Faculty of Medicine of the National Autonomous University of Mexico (UNAM), later he completed a master's degree and a doctorate in biomedical research, at the same institution. He did postdoctoral studies at Rockefeller University in New York. Career 
Alagón joined the faculty and researchers at the Institute of Biotechnology at his alma mater where he has been coordinator of master's and doctoral programs in biochemical sciences and academic secretary at the Center for Research on Genetic Engineering and Biotechnology. He has been instrumental in the development of antivenoms used throughout the Americas and Africa. In the USA he is known for his work on Anascorp, the first scorpion antivenom approved since the establishment of the modern FDA. He is currently a Professor Emeritus at the Institute of Biotechnology-UNAM. Awards and distinctions 

 National University Award (PUN) in the area of Innovation and Technology granted by the National Autonomous University of Mexico in 2004. National Prize for Arts and Sciences (Mexico) award granted by the Secretariat of Public Education (Mexico) in 2005. Premio Luis Elizondo award granted by the Monterrey Institute of Technology and Higher Education in 2013

References

Mexican physicians
Mexican academics
National Autonomous University of Mexico alumni
Year of birth missing (living people)
Living people
Toxinologists